Provided by Tiger Trade Technology Pte. Ltd.

Adial Pharmaceuticals

6.22
+0.31505.34%
Volume:81.99K
Turnover:493.98K
Market Cap:16.32M
PE:-0.35
High:6.41
Open:5.95
Low:5.74
Close:5.90
52wk High:10.75
52wk Low:1.31
Shares:2.63M
Float Shares:1.82M
Volume Ratio:0.92
T/O Rate:4.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.7100
EPS(LYR):-11.9306
ROE:-2011.66%
ROA:-40.08%
PB:-0.43
PE(LYR):-0.52

Loading ...

Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies

Reuters
·
Mar 24

Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate

Benzinga Earnings
·
Mar 06

Press Release: Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Dow Jones
·
Mar 06

Adial Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 06

Adial Pharma posts FY 2025 net loss of USD 8.0 million, down 40%

Reuters
·
Mar 06

Adial Pharmaceuticals enters collaboration framework agreement with Molteni

TIPRANKS
·
Mar 03

Adial Pharmaceuticals Signs Exclusive AD04 Collaboration Framework With Molteni for Europe

Reuters
·
Mar 03

Adial Pharmaceuticals Inc: Engaging With Potential Commercial Partners in United States, to Initiate Its Pivotal Phase 3 Program in Near Term

THOMSON REUTERS
·
Mar 03

Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement

THOMSON REUTERS
·
Mar 03

EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million

Benzinga_recent_news
·
Mar 03

Adial Pharmaceuticals Inc expected to post a loss of $2.15 a share - Earnings Preview

Reuters
·
Feb 27

BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement

Reuters
·
Feb 24

Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance

Reuters
·
Feb 24

Adial Pharmaceuticals Highlights FDA Shift Toward Single Pivotal Trial Backed by Confirmatory Evidence

Reuters
·
Feb 23